[HTML][HTML] PLK1 protects against sepsis-induced intestinal barrier dysfunction

Y Cao, Q Chen, Z Wang, T Yu, J Wu, X Jiang, X Jin… - Scientific Reports, 2018 - nature.com
Y Cao, Q Chen, Z Wang, T Yu, J Wu, X Jiang, X Jin, W Lu
Scientific Reports, 2018nature.com
Sepsis and sepsis-associated intestinal barrier dysfunction are common in intensive care
units, with high mortality. The aim of this study is to investigate whether Polo-like kinase 1
(PLK1) ameliorates sepsis-induced intestinal barrier dysfunction in the intestinal epithelium.
The mouse intestinal barrier was disrupted after Lipopolysaccharide (LPS) injection due to
intestinal epithelial cell apoptosis and proliferation inhibition, accompanied by decreased
PLK1. In HT-29 intestinal epithelial cells, LPS stimulation induced cell apoptosis and …
Abstract
Sepsis and sepsis-associated intestinal barrier dysfunction are common in intensive care units, with high mortality. The aim of this study is to investigate whether Polo-like kinase 1 (PLK1) ameliorates sepsis-induced intestinal barrier dysfunction in the intestinal epithelium. The mouse intestinal barrier was disrupted after Lipopolysaccharide (LPS) injection due to intestinal epithelial cell apoptosis and proliferation inhibition, accompanied by decreased PLK1. In HT-29 intestinal epithelial cells, LPS stimulation induced cell apoptosis and inhibited cell proliferation. Overexpression of PLK1 partly rescued the apoptosis and proliferation inhibition in HT29 cells caused by LPS. Finally, LPS stimulation promoted the reduction of PLK1, resulting in apoptosis and proliferation inhibition in intestinal epithelial cells, disrupting the intestinal epithelial barrier. These findings indicate that PLK1 might be a potential therapeutic target for the treatment of sepsis-induced intestinal barrier dysfunction.
nature.com